Compare · MDT vs PAVM

MDT vs PAVM

Side-by-side comparison of Medtronic plc. (MDT) and PAVmed Inc. (PAVM): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. MDT focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus, while PAVM focuses on Medical/Dental Instruments.
  • MDT is the larger of the two at $127.84B, about 14024.4x PAVM ($9.1M).
  • MDT has been more active in the news (14 items in the past 4 weeks vs 7 for PAVM).
  • MDT has more recent analyst coverage (25 ratings vs 0 for PAVM).
MetricMDTPAVM
Company
Medtronic plc.
PAVmed Inc.
Price
-
-
Market cap
$127.84B
$9.1M
1M return
+3.49%
-
1Y return
-3.18%
-
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Medical/Dental Instruments
Exchange
NYSE
NASDAQ
IPO
2016
News (4w)
14
7
Recent ratings
25
0
MDT

Medtronic plc.

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.

PAVM

PAVmed Inc.

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). Its product pipeline also comprises EsoGuard, a molecular diagnostic esophageal DNA test; EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; PortIO, an implantable intraosseous vascular access device; and DisappEAR, a resorbable pediatric ear tube, as well as NextCath and Caldus. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is based in New York, New York.

Latest MDT

Latest PAVM